Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Operating Officer

Chief Medical Officer

Interim CEO & General Counsel

Chief Financial Officer

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃƒÂ© de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy prod...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-15	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-04-15	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-04-15	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-04-15	Premium	sold (taxes)	Premium	Premium	Premium	Interim CEO & General Counsel
2024-04-15	Premium	acquired	Premium	Premium	Premium	Interim CEO & General Counsel
2024-04-15	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	Interim CEO & General Counsel
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	Interim CEO & General Counsel
2024-03-04	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-02-20	Premium	bought	Premium	Premium	Premium	-
2024-02-20	Premium	bought	Premium	Premium	Premium	-
2024-02-20	Premium	bought	Premium	Premium	Premium	-
2024-01-16	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-01-16	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-01-16	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-01-16	Premium	acquired	Premium	Premium	Premium	Interim CEO & General Counsel
2024-01-16	Premium	sold (taxes)	Premium	Premium	Premium	Interim CEO & General Counsel
2024-01-16	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-10-16	Premium	sold (taxes)	Premium	Premium	Premium	Interim CEO & General Counsel
2023-10-16	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2023-10-16	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-10-16	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer

IOVA - Iovance Biotherapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for IOVA